Ovid Therapeutics Inc. reported earnings results for the third quarter and nine months ended November 10, 2021. For the third quarter, the company reported net loss was USD 11.38 million compared to USD 16.42 million a year ago. Basic loss per share from continuing operations was USD 0.17 compared to USD 0.28 a year ago. Diluted loss per share from continuing operations was USD 0.17 compared to USD 0.28 a year ago. For the nine months, revenue was USD 208.38 million compared to USD 6.91 million a year ago. Net income was USD 148.83 million compared to net loss of USD 59.01 million a year ago. Basic earnings per share from continuing operations was USD 2.15 compared to basic loss per share from continuing operations of USD 1.04 a year ago. Diluted earnings per share from continuing operations was USD 2.14 compared to diluted loss per share from continuing operations of USD 1.04 a year ago.